Balyasny Asset Management
IMUX icon

Balyasny Asset Management’s Immunic IMUX Stock Holding History

Balyasny Asset Management’s Portfolio IMUX Stock Details IMUX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-39
Closed -$107K – 1943
2018
Q1 		$107K Buy
39
+13
+50% +$29.8K ﹤0.01% 1824
2017
Q4 		$61K Buy
+26
New +$57.5K ﹤0.01% 2001

Other funds holding IMUX

Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Balyasny Asset Management's IMUX Position: Q2 2018 in Review

Balyasny Asset Management sold out of Immunic (IMUX) in Q2 2018, closing a stake of 39 shares — an estimated $107K sold.

Balyasny Asset Management first reported a position in IMUX in Q4 2017 and held it in 2 quarters. The position peaked at $107K in Q1 2018. 62 funds tracked by Wall St. Rank hold IMUX as of Q2 2018.

  • Balyasny Asset Management reported no remaining Immunic position as of Q2 2018 after selling out during the quarter.
  • Balyasny Asset Management sold 39 Immunic shares in Q2 2018, an estimated $107K.
  • Balyasny Asset Management first reported a position in Immunic in Q4 2017 and held it in 2 quarters.
  • Balyasny Asset Management's Immunic position peaked at $107K in Q1 2018.
  • 62 funds tracked by Wall St. Rank held Immunic as of Q2 2018.

Based on Balyasny Asset Management's 13F filing for Q2 2018, filed 14 Aug 2018.